Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:05 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
April 22, 2022 08:00 ET
|
Vallon Pharmaceuticals Inc.
Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
February 28, 2022 16:05 ET
|
Vallon Pharmaceuticals Inc.
Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and...
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
February 12, 2021 15:30 ET
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...